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FACTOR VIII DEFICIENCY: INHIBITION OR ABNORMAL CONTACT?
OBJECTIVES 
Initiation of the intrinsic pathway occurs when prekallikrein, high-molecular-weight
kininogen, Factor XII (FXII) and FXI are exposed to a negatively charged
surface, interacting with the phospholipids of circulating lipoprotein particles (contact
phase). The working mechanism of FVIII inhibitors (autoantibodies) is time and
temperature-dependent. Both situations influence aPTT and their clarification can be
difficult.
The authors intend to present the case of a patient with increased aPTT and FVIII low
levels, with hematuria, whose diagnostic clarification has been very challenging.
METHODS 
Female, 22 years old, hospitalized for inaugural diabetes, secondary to corticoid
therapy (prednisolone) prescribed six months before for migratory oligoarthritis.
Sudden hematuria and aPTT elevation (60-120 sec), previous results border-line.
Microcytic hypochromic anemia since three years ago, due to menometrorrhagia
and H. pylori positive gastritis, Dress syndrome due to salazopirine and acute
hepatitis after ciprofloxacin treatment. Without previous transfusions or hemorrhagic
discrasia. Family history of rheumatoid arthritis, absence of hemorrhagia.
Preformed laboratorial investigation of aPTT elevation (HemosIL® Reagents).
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• F VIII activity levels average 2.3% (RV: 50-150%)
• F VIII inhibitor titer :1.05 to 4.5 BU
• F XII between 20% to 50.6% (RV: 50-150%; the lowest levels meet the highest
values for aPTT)
• All the other factors were in reference values, except for FvW R:Co (RV: 50-
180%) and FvW: Ag (RV: 50-180%) that were very high, probably due to the
inflammatory process
• Lupus anticoagulant were negative.
Medicated with ciclophosphamide, rituximab and prednisolone, with hematuria and
coagulation abnormalities resolution.
RESULTS 
Acquired hemophilia A in association with Factor XII inhibition
As referred in the literature, in this patient FVIII inhibitor did not correlated with FVIII levels.
Presence of FVIII inhibitors probably type 2 (second-order kinetics), as the FVIII was not complete inactivated. There was always a residual
concentration of Factor VIII, except in one occasion. Although the sudden hematuria was soon quelled, these autoantibodies presented a strong
resistance to immunosuppressant therapy, even with low titers of antibody.
The exuberance of APTT (>120”) measurements coincided with the lowest FVIII (<1%) and FXII (20%) levels. All the other coagulation factors were
between the reference values.
With the eradication of the antibodies and normalization of Factor VIII levels, FXII also increased (to borderline levels of 50%) and aPTT normalized.
Did FVIII inhibitor also inhibited FXII?
CONCLUSIONS 
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